State Council announced the “General Plan of Nansha, Guangzhou for Deepening Globally Oriented Comprehensive Co-operation amongst Guangdong, Hong Kong and Macau” (Nansha Plan) in June 2022 and implemented taxation rate adjustment in Nansha recently. Dr. LI Xiaoyi, the Founder and Director of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was interviewed by Southern Finance Omnimedia Group about the benefits of Nansha Plan that illustrate the development in pharmaceutical industry and advancement of technology.

The rare disease community has received increased public attention as Chinese authorities has issued a circular on further promoting the prevention and control measures, while strengthening the supportive care needs of patients with rare diseases. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), China Alliance for Rare Diseases, RDPAC, China Pharmaceutical Innovation and Research Development Association, China National Pharmaceutical Industry Information Center, domestic and international enterprises jointly announced the proposal of“Caring for Rare Disease Community and Achieving Social Harmony” during the 2022 China Conference on Rare Diseases held on 29 October 2022.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the “Most Valuable Companies in Hong Kong 2022 Awards” by Mediazone Group, an international business magazine publisher, in recognition of its extensive research and development experience and solid infrastructures. Please refer to the link below for a full media coverage by Mediazone Group. http://www.mediazone.com.hk/hkmvc/2022/11/08/revolutionizing-healthcare-through-innovative-drug-research-development/

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on 26 October 2022, AU409, an investigational new drug candidate, drug product manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited (“Zhaoke Guangzhou”), a wholly-owned subsidiary of the Group, has been approved by the United States Food and Drug Administration (“US FDA”) to conduct clinical trial in patients with advanced primary liver cancers or advanced solid tumor with liver predominant metastatic disease in the United States.

Lee’s Pharm has collaborated with Lok Sin Tong Community Pharmacy to donate a total of 900 boxes of masks to support the community. Please contact Lok Sin Tong Community Pharmacy for more details.

Recently, the China National Intellectual Property Administration (CNIPA) announced the honours list of “2022 Excellent Enterprise and Role Model Enterprise of China National Intellectual Property”. Having strong innovative capabilities in research and development and well-established intellectual property management system, Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was recognized as “2022 Excellent Enterprise of National Intellectual Property”, only one biopharmaceutical company in Anhui Province was awarded.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on September 20, 2022, the marketing authorization for generics of Azilsartan tablets (specification: 20mg), developed and manufactured by the Group, has been obtained from the China National Medical Products Administration (“NMPA”) (國藥准字H20223680). The drug has been approved to treat hypertension.

Hong Kong, September 3, 2022, “the Healthcare and Biotech Road Map in Greater Bay Area” Symposium, sponsored by Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), was successfully held both virtually and physically at the center of Hong Kong Management Association. Lee’s Pharm was awarded with the certificate issued by Greater Bay Area Medical Professional Study Group for its steadfast support and generosity.

Hong Kong, August 12-14, 2022, the Jiangsu Psychiatry Conference 2022, co-organized by the Jiangsu Medical Association and its branch Psychiatric Association, was successfully held in Jiangsu, China. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) kicked off a Satellite Meeting for Trittico®, the New “Excellent” Treatment for Depression, as to facilitate the intellectual interaction among the field of psychiatry.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) has been recognized again as a “Caring Company” by The Hong Kong Council of Social Service (HKCSS). Lee’s Pharm attained Caring Company Award Logo for consecutive two years with good corporate citizenship recognition.

LOS ALTOS, Calif., July 18, 2022 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has entered into an agreement granting exclusive rights to develop, market and commercialize Renazorb® (lanthanum dioxycarbonate) to Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”)(SEHK: 950), in Mainland China, Hong Kong, and certain other Asian markets. Renazorb is Unicycive’s novel phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.

The 2022 China Medical and Health Industry Symbiosis Conference, organized by Menet, the healthcare information platform was held in Huzhou, Zhejiang Province, China from 12 to 15 July, 2022. The lists of “Top 100 ranking of Chinese Pharmaceutical Industry”, “Top Brand of Chinese Pharmaceuticals” and “2022 Most Valuable Product in Partnership for Drug Store Chain in China” were released. The in-licensed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), Ferplex® was elected as “2022 Most Valuable Product in Partnership for Drug Store Chain in China”.